Indomethacin decreases insulin secretion in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 49, Issue 7, 2000, Pages 839-844

  Pereira Arias, Alberto M ^a,b,c   Romijn, Johannes A ^a,b,c   Corssmit, Eleonora P M ^a,b,c   Ackermans, Mariette T ^a,b,c   Nijpels, Giel ^a,b,c   Endert, Erik ^a,b,c   Sauerwein, Hans P ^a,b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INDOMETACIN; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HUMAN; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0034235061     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2000.6748     Document Type: Article

References (29)

1. 1. Bowen HF, Moorhouse JA: Glucose turnover and disposal in maturity-onset diabetes. J Clin Invest 52:3033-3045, 1973
2. 2. DeFronzo RA, Ferrannini E, Simonson DC: Fasting hyperglycemia in non-insulin dependent diabetes mellitus: Contributions to excessive glucose production and impaired glucose uptake. Metabolism 38:387-395, 1989
3. 3. Glauber H, Wallace P, Brechtel G: Effects of fasting on plasma glucose and prolonged tracer measurement of hepatic glucose output in NIDDM. Diabetes 36:1187-1194, 1987
4. 3H-glucose infusion. Diabetologia 33:603-610, 1990
5. 5. Consoli A, Nurjhan N, Reilly J, et al: Mechanism of increased gluconeogenesis in NIDDM. J Clin Invest 86:2038-2045, 1990
6. 6. Mevorach M, Giacca A, Aharon Y, et al: Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 102:744-753, 1998
7. 7. Müller MJ, Möller J, Seitz HJ: Regulation of hepatic glucose output by glucose in vivo. Metabolism 37:55-60, 1988
8. 8. Decker K: Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 192:245-261, 1990
9. 9. Magilavy DB, Rothstein JL: Spontaneous production of tumor necrosis factor α by Kupffer cells of MRL/1pr mice. J Exp Med 168:789-794, 1988
10. 10. Casteleijn E, Kuiper J, van Rooij HC, et al: Hormonal control of glycogenolysis in parenchymal liver cells by Kupffer and endothelial liver cells. J Biol Chem 263:2699-2703, 1988
11. 11. Horton RA, Ceppi ED, Knowles RG, et al: Inhibition of hepatic gluconeogenesis by nitric oxide: A comparison with endotoxemic shock. Biochem J 299:735-739, 1994
12. 12. Corssmit EPM, Romijn JA, Endert E, et al: Indomethacin stimulates basal glucose production in humans without changes in concentrations of glucoregulatory hormones. Clin Sci (Colch) 85:679-685, 1993
13. 13. Dekker E, Romijn JA, van Thien H, et al: Indomethacin stimulates glucose production in adults with uncomplicated falciparum malaria. Metabolism 47:217-222, 1998
14. 14. Reinauer H, Gries FA, Hubinger A, et al: Determination of glucose turnover and glucose oxidation rates in man with stable isotope tracers. J Clin Chem Clin Biochem 28:505-511, 1990
15. 15. Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420-430, 1959
16. 16. Lilavivathana U, Brodows RG, Woolf PD, et al: Counterregulatory hormonal responses to glucose lowering in diabetic man. Diabetes 28:873-877, 1979
17. 17. Vigas M, Klimes I, Jurcovicova J, et al: Inhibition of L-dopa induced growth hormone release in normal and diabetic subjects by glucose administration. Diabete Metab 3:257-258, 1977
18. 18. Sindelar DK, Chu CA, Venson P, et al: Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 47:523-529, 1998
19. 19. Topol E, Brodows RG: Effects of indomethacin on acute insulin release in man. Diabetes 29:379-382, 1980
20. 20. Luycks AS, Guerten D, Scheen A, et al: Effect of indomethacin on the metabolic and hormonal response to a standardized breakfast in normal subjects. Acta Diabetol Latina 18:259-266, 1981
21. 21. Robertson RP: PGE, carbohydrate homeostasis and insulin secretion. A suggested resolution of the controversy. Diabetes 32:231-234, 1983
22. 22. Robertson RP, Gaverski DJ, Porte D Jr, et al: Inhibition of in vivo insulin secretion by prostaglandin E1. J Clin Invest 54:310-315, 1974
23. 23. Endres S, Cannon JG, Ghorbani R, et al: In vitro production of IL 1β, IL 1α, TNF and IL 2 in healthy subjects: Distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 19:2327-2333, 1989
24. 24. McDaniel ML, Kwon G, Hill JR, et al: Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 211:24-32, 1996
25. 25. Schmitt JK: Indomethacin increases plasma growth hormone levels in man. Am J Med Sci 300:144-147, 1990
26. 26. Schmitt JK: Ibuprofen fails to increase plasma growth hormone levels in humans. Am J Med Sci 305:289-291, 1993
27. 27. Honegger J, Spagnoli A, D'Urso R, et al: Interleukin-1 beta modulates the acute increase of growth hormone-releasing hormone and somatostatin from rat hypothalamus in vitro, whereas tumor necrosis factor and interleukin-6 have no effect. Endocrinology 129: 1275-1282, 1991
28. 28. Christensen JR, Hammond BJ, Smith GD: Indomethacin inhibits endocytosis and degradation of insulin. Biochem Biophys Res Commun 173:127-133, 1990
29. 29. Kulkarni RN, Bruning JC, Winnay JN, et al: Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96:329-339, 1999